Post-market clinical follow-up applies to all medical devices, of all classes, and is required under EU MDR with very few exceptions. Beyond EUMDR, in 2022, 45% of the original Premarket Approvals (PMAs) granted by the FDA require post-approval studies. With limited time and resources, manufacturers are forced to make the choice of which devices to prioritize. 3Aware provides aiSurveillance for medical device manufacturers to save time and money by offering Access, Analysis and Alerts of real-world clinical data. This approach is faster and more cost effective for manufacturers, requires less effort by hospitals and their providers which leads to better patient outcomes.

Lea’s Foundation for Leukemia Research, Inc. was established in 1998 to fund research into the causes of, and cures for, leukemia and its related cancers of Lymphoma, Hodgkin’s Lymphoma and Myeloma. Since its inception, over 6 million dollars has been raised to help others celebrate life and to benefit those suffering from leukemia and other blood disorders. Lea's Foundation can proudly say that it gives away approximately 95% of all money raised, 100% of Lea's Foundation board members are volunteers with a passion for helping others, and our Patient Assistance and Life Assistance programs have helped over 200 families. Over $5 million dollars have gone directly to medical research and other health related programs at the following hospitals: UCONN Health Center, Saint Francis/Mount Sinai, Connecticut Children's Medical Center, Mercy Medical Center - Springfield, MA, and Yale New Haven Children's Hospital.

As Chief Executive Officer, I led the transformation of an academia focused life sciences company into the industry’s leading bioinformatics ecosystem provider to both commercial biopharma and government programs, evolving the company culture, strategy and operational/financial disciplines, generating exceptional growth in revenue / gross margin and significantly increasing valuation in less than 4 years, resulting in the acquisition by Summa Equity. Seven Bridges (acquired by Summa Equity in 2022) enabled researchers worldwide toextract meaningful insights from genomic data in order to advance precision medicine with offices in the US, UK, Serbia, Turkey and throughout central Europe. Our complete bioinformatics ecosystem consists of a compliant analytics platform, seamless data and automation, transforming analytic solutions, and expert scientific services. This holistic approach to bioinformatics is enables researchers - at the world’s leading academic, biotechnology, government, medical centers, and pharmaceutical entities - to increase R&D efficiency, enhance hypothesis resolution, isolate critical biomarkers, and even turn failing clinical into successes. Ultimately, reducing the time, cost, and risk associated with new product development in order to bring more life-changing products to market earlier. In doing so, the Seven Bridges team supports thousands of researchers in biopharma, government, and academia, as well as some of the world's largest national genomics research programs, including: >20 of the top 30 largest commercial biopharma companies, many bio-techs, and various programs under NIH, NHLBI, NCI, NIAID, NIA, VA, Genomics England, UK Biobank and others.

As Founder and CEO, conceived, incubated and led the launch a spin out subsidiary - inparallel with Seven Bridges – to formulate an unprecedented multi-sided market approach to optimize the collaboration of biopharma, health systems and patients to accelerate the advancement and application of precision medicines, securing participation from leading US health systems and academic medical centers with access to >20M patients and their data, resulting in acquisition by Summa Equity.The Unified Patient Network (acquired by Summa Equity in 2022) was a new subsidiary spun out of Seven Bridges Genomics, providing a community precision health ecosystem that facilitates commercial, research and clinical collaboration between the UPN health system members, their patients and biopharma research entities. The UPN was designed to accelerate scientific advancement and clinicalimplementation of precision medicine, in a manner that provides truly unprecedented return-of-value to its health system members and their patients. The UPN network includes health system members such as Washington University, BJC, Providence, St. Josephs, University of Pittsburgh and UPMC, with access to over 20M patients and their data.

As EVP of Strategic Planning & Business Development, I led the realignment offerings to specific ‘underserved’ industry needs, establishing it as the premier solution in target market sectors, generating >$60M in total contract value over first 2.5 years in the market.TruthMD’s mission is to be the world’s most trusted source of immediately-actionable truth regarding healthcare practitioners, entities and institutions, in order to improve healthcare through increased transparency and accountability in a sustainable process of continuous automated vigilance.

MFX is a technology company providing critical business support in the fields of insurance applications solutions targeted to the Commercial Property and Casualty industry provided through an on-demand, fully-hosted delivery model, and Managed Infrastructure Services which MFX provides to all industries.

As President & COO, re-invigorated a medical professional liability insurance software/SaaS/services provider into a state of stable growth and profitability, achieving >100% growth in total revenue with >20% profitability within two years, with a 300% increase in recurring SaaS revenues, ultimately later being acquired by Sapiens.Delphi Technology provides industry leading products and services for mission critical, end-to-end business processing and analytics within the commercial lines insurance industry with a focus on medical professional liability and other specialty product lines. Our clients included: Medical Protective, MLMIC, PRI, NORCAL, MICA, MMIC Group, MAG Mutual, BCS Group and others.

Delphi Technology provides industry leading products and services for mission critical, end-to-end business processing and analytics within the commercial lines insurance industry with a focus on medical professional liability and other specialty product lines. Our clients included: Medical Protective, MLMIC, PRI, NORCAL, MICA, MMIC Group, MAG Mutual, BCS Group and others.

As GM, I led a corporate spin out that transformed an unprofitable high-volume pharma distribution software/services provider into a state of rapid growth and profitability, generating $2M+ of EBITDA and $20M+ in total first year contracts, more than doubling transaction volumes and recurring revenue within two years, and ultimately growing revenue from under $5M to over $70M with 24% EBITDA in ~ 4 years, resulting in being acquired by McKesson Corporation.The High Volume Pharmacy Solutions business unit, which was acquired sequentially by NDCHealth, Per Se Technologies Inc. and McKesson Corporation, provided end-to-end point of sale, order intake, order processing, adjudication, fulfillment automation, inventory management and operations management capabilities to high volume mail order/central fill distribution centers for retail pharmacy chains and pharmacy benefit managers. Our clients included: Eckerds, CVS, Raley's, Krogers, Cigna Tel Drug, Humana, Anthem/WellPoint, Kaiser Permanente and others.

As SVP of Business Development, drove rapid growth of VC backed early-stage retail pharmacy systems company to $80M+ in annual revenue, enabling >4X investor return in a strategic acquisition by NDC Health Corporation.TechRx was the nations leading provider of retail pharmacy solutions for end-to-end point of sale, order intake, order processing, adjudication, fulfillment automation, inventory management and operations management. Our clients included: Eckerds, CVS, Krogers, Ahold, Publix and others. TechRx was acquired by NDCHealth, in the first of a series of strategic acquisitions.

As VP & GM, conceived/implemented new Strategic Solutions Group for a leading P&C insurance software/services provider, re-engineering their legacy technology solution to access the Tier 1 ecommerce market, resulting in $6.8M+ revenue and $40M+ in total contracts value during our first year from inception, and >50% YOY growth going forward.AMS Rating Services (a privately held Marsh & McLennan Company) was the leading provider of property & casualty insurance point of sale, rating and processing software & service solutions, with a 25 year history of serving the low to mid range markets.

As Vice President of Sales, spearheaded business development for a VC backed start-up, providing business systems conversion and remediation services, resulting in a 500%+ return for VC investors in <3 years, with $4.8M of new revenue and $16M+ new contract value during company’s first year of existence and >100% growth in year two, resulting in acquisition by Mantech International.REVIVE was the industry's leading provider of business systems conversion and remediation tools & services, with a focus on migrating large financial services and insurance back office systems off of mainframe infrastructures and non relation data bases to modern distributed and relational environments.

SDRC was a world leading provider of product data management and computer aided engineering, analytic & manufacturing solutions. SDRC was eventually acquired by EDS.

SDRC was a world leading provider of product data management and computer aided engineering, analytic & manufacturing solutions. SDRC was eventually acquired by EDS.

Hazeltine was a leading provider of military avionic, antenna array and target identification systems for the United States Department of Defense and various allies. Hazeltine was eventually acquired by BAE Systems.